ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1413

Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

Mark Matza1, Adam Jarvie2, Ana Fernandes1, John Stone3 and Sebastian Unizony4, 1Massachusetts General Hospital, Boston, MA, 2Masssachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Winchester, MA

Meeting: ACR Convergence 2021

Keywords: giant cell arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis (GCA). Therefore, we evaluated the efficacy and safety of TCZ in combination with 2 months of prednisone in a group of patients with GCA.

Methods: We conducted a prospective, single arm, open-label study of TCZ in combination with 2 months of prednisone for new-onset and relapsing GCA patients with active disease. GCA diagnosis required confirmation by temporal artery biopsy or vascular imaging. Active disease was defined as presence of cranial or polymyalgia rheumatica symptoms needing treatment within 6 weeks of baseline. All patients received TCZ 162 mg subcutaneously every week for 12 months and an 8-week prednisone taper starting between 20 mg and 60 mg daily. The primary endpoint, sustained prednisone-free remission, was defined as absence of relapse from induction of remission up to week 52 while adhering to the prednisone taper. Relapse was defined as recurrence of symptoms of GCA requiring treatment intensification, regardless of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. Safety was also evaluated.

Results: Between 11/2018 and 11/2020 we enrolled 30 patients (mean age 74 years, 60% female, 97% Caucasian, 57% new-onset disease, 77% temporal artery biopsy-proven, 47% imaging-proven) (Table 1). The mean ESR and CRP at screening were 50.3 mm/hour and 53.2 mg/L, respectively. At this moment, 22 patients have completed the study treatment protocol and 8 patients have yet to reach week 52 (mean follow up 35 weeks). Here we report the outcomes of the 22 patients that have completed the study. The initial prednisone dose in this group was 60 mg (n = 6), 40 mg (n = 7), 30 mg (n = 4), and 20 mg (n = 5). All patients entered remission within 4 weeks of baseline. The primary endpoint was achieved by 18 (82%) patients (Table 2). The mean (SD) cumulative prednisone dose in these 18 patients was 1,037 (367) mg. After a mean period of 20.5 weeks, 4 (18%) patients relapsed (Table 2). All relapses occurred after the completion of the prednisone taper. Overall, 4 (18%) participants developed a serious adverse event (Table 2). No cases of vision loss occurred during the study.

Conclusion: Pending the final analysis of this pilot study, the results presented here suggest that 12 months of TCZ in combination with 8 weeks of prednisone could be efficacious for maintaining disease remission in patients with GCA. Confirmation of these findings in a randomized controlled trial is required.

Table 1 shows patient baseline characteristics

Table 2 shows outcomes for the 22 patients who have completed the treatment protocol to date


Disclosures: M. Matza, None; A. Jarvie, None; A. Fernandes, None; J. Stone, Principia Biopharma Inc, a Sanofi Company, 5, 12, personal fees; S. Unizony, Genentech, 5, Sanofi-Aventis, 2, Kiniksa Pharmaceuticals, 2.

To cite this abstract in AMA style:

Matza M, Jarvie A, Fernandes A, Stone J, Unizony S. Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/tocilizumab-in-combination-with-8-weeks-of-prednisone-for-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-in-combination-with-8-weeks-of-prednisone-for-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology